Registration number: 08481873

Biogest UK Ltd

Contents

Balance Sheet	1
Notes to the Financial Statements	2

Biogest UK Ltd

(Registration number: 08481873)
Balance Sheet as at 31 December 2024

	Note	2024 £	2023 £
Fixed assets
Tangible assets	5	37,080	15,038
Current assets
Debtors	6	883,269	703,650
Cash and cash equivalents		107,394	101,227
		990,663	804,877
Creditors: Amounts falling due within one year	7	(1,448,142)	(913,657)
Net current liabilities		(457,479)	(108,780)
Net liabilities		(420,399)	(93,742)
Capital and reserves
Allotted, called up and fully paid share capital	8	1	1
Retained earnings	8	(420,400)	(93,743)
Total equity		(420,399)	(93,742)

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the directors have not delivered to the registrar a copy of the Profit and Loss Account.

These financial statements were approved and authorised by the Board on 23 September 2025 and signed on its behalf by:
 

.........................................

M Schlerka

Director

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024

1	General information

Biogest UK Ltd (the 'company') is a private limited company by share capital, registered in England and Wales under the Companies Act. The address of the registered office is given on page 1. The nature of the company's operations and its principal activities are set out in the directors' report on page 2.

2	Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

The functional currency of the company is considered to be pounds sterling (£) because that is that currency of the primary economic environment in which the company operates. The financial statements are presented in sterling (£).

Going concern
The directors have considered the impact of future performance together with financial projections for the company over the foreseeable future and have also reviewed the ongoing committed financial support from the company's parent undertaking and are confident that this will be available for the foreseeable future. After making enquiries, the directors are satisfied that the company has sufficient resources to continue in operation for the foreseeable future, being at least 12 months from the date of signing the financial statements. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

Biogest UK Ltd is reliant on the support of Bioquadrat Energie- und Wassertechnik Holding GmbH as the parent company which is committed to the UK market and has demonstrated its support through a letter of support.

Exemption from preparing a cash flow statement
The company meets the definition of a small entity under FRS 102 and has therefore taken advantage of the disclosure exemptions from the requirement to present a statement of cash flows provided under paragraph 1A.7 of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024 (continued)

Audit report

The Independent Auditor's Report was unqualified. The name of the Senior Statutory Auditor who signed the audit report on 23 September 2025 was Ransford Agyei-Boamah, who signed for and on behalf of Shaw Gibbs (Audit) Limited.

Reclassification of comparative amounts

IT licences and software costs totalling £6,538 have been reclassified from sales and marketing costs to administrative expenses in order to better reflect the nature of expenditure.

Trade debtors totalling £376,205 have been reclassified to amounts owed by group and associated undertakings to reflect debts receivable from affiliated entities.

Revenue recognition

Revenue comprises the fair value of the consideration received or receivable for the provision of services in the ordinary course of the company’s activities. Revenue is shown net of value added tax.

The company recognises revenue when the amount of revenue can be reliably measured; it is probable that future economic benefits will flow to the entity; and specific criteria have been met for each of the company's activities.

Foreign currency transactions and balances

Transactions in foreign currencies are initially recorded at the functional currency rate prevailing at the date of the transaction. Monetary assets and liabilities denominated in foreign currencies are retranslated into the respective functional currency of the entity at the rates prevailing on the reporting period date. Non-monetary items carried at fair value that are denominated in foreign currencies are retranslated at the rates prevailing on the initial transaction dates.

Non-monetary items measured in terms of historical cost in a foreign currency are not retranslated.

Tangible assets

Tangible assets are stated in the balance sheet at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Furniture, fittings and office equipment	25% straight line basis
Motor vehicles	25% straight line basis

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and held at bank.

Debtors

Debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024 (continued)

Creditors

Creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Creditors are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method where due after more than one year.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Defined contribution pension obligation

The company operates a defined contribution pension scheme. The assets of the schemes are held separately from those of the company. Contributions are recognised in the income statement in the period in which they become payable.

3	Critical accounting judgements and key sources of estimation uncertainty

In the application of the company's accounting policies, which are described in note 2, the directors are required to make judgements, estimates and assumptions about the carrying amounts of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates. There has been no significant judgements in accounting policy.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised if the revision affects only that period, or in the period of the revision and future periods if the revision affects both current and future periods.

4	Staff numbers

The average number of persons employed by the company (including directors) during the year, was 15 (2023 - 16).

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024 (continued)

5	Tangible assets

	Motor vehicles  £	Furniture, fittings and office equipment  £	Total £
Cost
At 1 January 2024	92,020	-	92,020
Additions	27,150	838	27,988
At 31 December 2024	119,170	838	120,008
Depreciation
At 1 January 2024	76,982	-	76,982
Charge for the year	5,876	70	5,946
At 31 December 2024	82,858	70	82,928
Carrying amount
At 31 December 2024	36,312	768	37,080
At 31 December 2023	15,038	-	15,038

6

Debtors

	2024 £	2023 £
Trade debtors	108,541	83,593
Amounts owed by group and associated undertakings	734,167	457,567
Other debtors	40,561	162,490
	883,269	703,650

Details of non-current trade and other debtors

£180,826 (2023 -£Nil) of amounts owed by group and associated undertakings is classified as non current.

Amounts owed by group undertakings disclosed as falling within one year includes loans of £415,814 (2023 - £nil) which are unsecured, repayable on demand and interest charged at 10.5%.

Other amounts owed by group undertakings include loans of £236,991 (2023 - £nil) which are unsecured and non-interest bearing, being repayable in 18 monthly instalments in accordance with debt settlement agreements.

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024 (continued)

7

Creditors

		2024 £	2023 £
Due within one year
Trade creditors		191,593	160,839
Amounts owed to group and associated undertakings		1,118,786	634,343
Taxation and social security		129,803	69,439
Other creditors		7,960	49,036
		1,448,142	913,657

The amount owed to group undertakings disclosed as falling within one year includes loans of £887,553 (2023 - £483,003) which are unsecured, payable on demand and interest charged at 10.5% (2023 - 8.1875%). All other loan balances are unsecured, payable on demand and are non-interest bearing.

8	Share capital and reserves

Allotted, called up and fully paid shares

	2024		2023
	No.	£	No.	£
Ordinary shares of £1 each	1	1	1	1

The company has one class of share capital which carries no right to fixed income.

Reserves
The retained earnings reserve represents cumulative profit or losses net of dividends paid and other adjustments.

9	Pension scheme

Defined contribution pension scheme

The company operates a defined contribution pension scheme. The pension cost charge for the year represents contributions payable by the company to the scheme and amounted to £12,143 (2023 - £12,302).

Contributions totalling £Nil (2023 - £nil) were payable to the scheme at the end of the year and are included in creditors.

Biogest UK Ltd

Notes to the Financial Statements for the Year Ended 31 December 2024 (continued)

10	Parent and ultimate parent undertaking

The company's immediate and ultimate parent is Bioquadrat Energie- und Wassertechnik Holding GmbH, incorporated in Austria.

The largest and smallest parent entity producing publicly available financial statements is Bioquadrat Energie- und Wassertechnik Holding GmbH. These financial statements are available upon request from THE ICON VIENNA Central Station, Gertrude-Froehlich-Sandner-Straße 2-4, Tower 9, Floor 9, A-1100 Vienna, Austria.

11	Related party transactions

The company is a wholly owned subsidiary member of its group and has therefore taken advantage of the provisions of paragraph 1AC.35 of FRS 102 - Small Entities not to disclose transactions with entities that are wholly owned members of the group.

There were no other related party transactions to disclose.

12	Events after the financial period

There have been no significant events between the year end and the date of approval of these financial statements which would require a change to, or disclosure in, the financial statements.